Redona Therapeutics
redonatx.com
Health Care
Biotechnology
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
1
Sofinnova Partners
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
Backed byfrom the funds' portfolios and accelerator catalogs
Sofinnova Partners Investors in similar startupsfunds that back the companies most like this one
backs Archbee, Pando Bioscience
backs Rhelixa
backs STORM Therapeutics
backs STORM Therapeutics
backs Lassen
Similar startupsby what they do, their industry and backers
ゲノム （ DNA ）、エピゲノム、トランスクリプトーム （ RNA ）を独自の技術で解析し、研究開発の効率・精度を格段に向上させます。次世代シーケンス（ NGS ）／ エピジェネティクス 研究の 実験デザイン から 情報 解析、論文化、事業化までオーダーメイドで支援します。.
Build Learn Contribute More Build Learn Contribute More Who we Are Who we Are.
ProQR is a biotech company that discovers and develops unique RNA therapies for severe rare and common diseases, based in Leiden, The…
Build beautiful knowledge portals that are easy to navigate, search, share and contribute to.
STORM Therapeutics is a pioneer in the field of RNA epigenetics. We are an emerging biotechnology company in Cambridge, UK, focused on…
Lassen Therapeutics is developing novel, best-in-class biotherapeutics to improve the lives of patients suffering from serious diseases.
News
Redona Therapeutics
Research outputs, collaborations and relationships for Redona Therapeutics
Read more
Report
AACR 2023: Genetic and pharmacological inhibition of TUT4/TUT7 sensitizes AML cells to BCL-2 inhibition
The post AACR 2023: Genetic and pharmacological inhibition of TUT4/TUT7 sensitizes AML cells to BCL-2 inhibition appeared first on Redona Therapeutics.
Read more
Report
AACR 2022: Selective inhibition of ZCCHC11/ZCCHC6 TUTaseswith genetic and pharmacological tools supports a role in Glioblastoma cell growth
The post AACR 2022: Selective inhibition of ZCCHC11/ZCCHC6 TUTaseswith genetic and pharmacological tools supports a role in Glioblastoma cell growth appeared first on Redona Therapeutics.
Read more
Report
28-7 Named Top Ten Academic Spinout of 2019
28-7 was selected as one of the most notable academic spinouts of 2019 by Nature Biotechnology. We greatly appreciate the special honor bestowed by the journal's editors. We invite you to read the full Nature Biotechnology article here. The post 28-7 Name
Read more
Report
28-7 named by Biospace to NextGen Bio "Class of 2020"
28-7 was recognized as a top biotech to watch in 2020 by Biospace and the highest ranking company dedicated to RNA. We are honored to receive this recognition, so early in the company's history, and we have every intention of fulfilling our mission to be
Read more
Report
Top European VC leads 28-7's Series A extension with $15 million and brings financing to over $80 million
Sofinnova Partners, a leading European venture capital firm specialized in the life sciences, today announced that the firm led Twentyeight-Seven's Series A extension with a $15 million investment. In addition to Sofinnova Partners, Osage University Partn
Read more
Report
Twentyeight-Seven Therapeutics launches to boost anticancer microRNA with small-molecule drugs
Twentyeight-Seven (28-7) Therapeutics is the latest start-up to launch with the goal of developing drugs that tackle the tricky interface between RNA and proteins. And it's got a whopping $65 million in series A financing to do it.
Read more
Report
Boston-Harvard Spinout 28-7 Launches with $65M for MicroRNA Cancer Drugs
Tackling tumors head-on isn't the only way to treat cancer. New cancer biotech 28-7 Therapeutics, a Harvard spinout, is researching an approach that targets cellular fragments that play key roles in cancer growth, and it now has $65 million in funding to
Read more
Report
MPM, Novartis lead a big launch round for Kazumi Shiosaki's latest biotech startup coming out of Harvard
Kazumi Shiosaki has now wrapped her third launch round for a biotech startup. The MPM Capital executive partner who helped found and initially ran Epizyme and Mitobridge has been working with a small team to help validate the decade-long effort at George
Read more
Report
28-7 Therapeutics raises $65M for cancer drugs aimed at tumor-suppressing RNAs
Founded in 2016, the company's core technology comes from four Harvard Medical School professors in biological chemistry, molecular pharmacology and RNA medicine: Richard Gregory, Ph.D.; Frank Slack, Ph.D.; Piotr Sliz, Ph.D.; and George Daley, M.D., Ph.D.
Read more
Report
Show more news